CLL Coverage from Every Angle

Jennifer Crombie, MD, on the Challenges of Using Duvelisib and Venetoclax in Patients With Relapsed or Refractory CLL/SLL

Posted: Thursday, January 2, 2020

Jennifer Crombie, MD, of Dana-Farber Cancer Institute, discusses the high rates of hematologic toxicities seen with this doublet, how she prepares patients for this regimen, and what she has found to be the best ways of managing common toxicities when they occur.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.